Share
Mark Egerton
Panthera Biopartners, the UK’s leading Site Management Organisation (SMO) supporting commercial clinical trials for the pharmaceutical and biotech industries, has appointed Mark Egerton as Chairman.
This strategic leadership addition comes as Panthera continues to strengthen its position as a premier partner for patient recruitment and clinical trial delivery across its rapidly expanding network of dedicated research sites.
Mark Egerton brings a wealth of experience from both the UK and U.S. pharmaceutical sectors, with a distinguished career marked by scaling organizations and driving international growth. He currently serves as Chairman of Newmarket Strategy, where he supports healthcare and life sciences organizations in navigating complex strategic and operational challenges. Previously, he served as Chief Executive Officer of Quotient Sciences, leading the company through a period of substantial expansion, including the growth of global operations and enhanced service capabilities. His leadership helped transform Quotient into a leading drug development accelerator with an international footprint.
Panthera Biopartners, founded in 2019, has quickly evolved into a trusted partner for global pharma and biotech companies by providing streamlined clinical trial delivery and significantly improving patient recruitment timelines. With a growing network of purpose-built clinical trial sites, Panthera continues to innovate in site operations, patient engagement, and trial management.
Mark Egerton’s appointment signals Panthera’s commitment to strengthening its governance and strategic vision as the company enters its next phase of growth. His expertise will support Panthera in expanding its operational capabilities, deepening industry partnerships, and advancing its mission to improve clinical trial efficiency worldwide.
